2018 Press Releases

Keyword Search
 
2018 | 2017 | 2016 | 2015 | 2014
Nov 23, 2018
Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Nov 8, 2018
Kala Pharmaceuticals Reports Third Quarter 2018 Financial Results
Nov 7, 2018
Kala Pharmaceuticals to Present at the Jefferies 2018 London Healthcare Conference
Oct 25, 2018
Kala Pharmaceuticals Appoints Steven Zhang as Vice President of Medical Affairs
Oct 19, 2018
Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Oct 18, 2018
Kala Pharmaceuticals to Present at the 2018 American Academy of Ophthalmology (AAO) Annual Meeting and at the Ophthalmology Innovation Summit at AAO
Oct 16, 2018
Kala Pharmaceuticals Submits New Drug Application to U.S. Food and Drug Administration for KPI-121 0.25% for Dry Eye Disease
Oct 11, 2018
Kala Pharmaceuticals Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares
Oct 3, 2018
Kala Pharmaceuticals Announces Pricing of Public Offering of 7,500,000 Shares of Common Stock
Oct 2, 2018
Kala Pharmaceuticals Announces Financing from Athyrium Capital Management Totaling $110 Million
Oct 2, 2018
Kala Pharmaceuticals Announces Proposed Public Offering of Common Stock
Sep 21, 2018
Kala Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Aug 29, 2018
Kala Pharmaceuticals to Present at Upcoming Investor Conferences
Aug 23, 2018
Kala Pharmaceuticals Announces FDA Approval of INVELTYS™ for the Treatment of Post-Operative Inflammation and Pain Following Ocular Surgery
Aug 9, 2018
Kala Pharmaceuticals Reports Second Quarter 2018 Financial Results
Aug 8, 2018
Kala Pharmaceuticals to Present at the Wedbush PacGrow Healthcare Conference
Jul 31, 2018
Kala Pharmaceuticals Announces Dosing of First Patient in Phase 3 STRIDE 3 Trial of KPI-121 0.25% in Patients with Dry Eye Disease
Jun 19, 2018
Kala Pharmaceuticals Announces Update to KPI-121 0.25% Development Plan
May 10, 2018
Kala Pharmaceuticals Reports First Quarter 2018 Financial Results
May 9, 2018
Kala Pharmaceuticals Strengthens Commercial Organization in Preparation for First Product Launch
May 8, 2018
Kala Pharmaceuticals to Present at Upcoming Investor Conferences
Apr 9, 2018
Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Apr 9, 2018
Kala Pharmaceuticals to Present at the 2018 American Society of Cataract and Refractive Surgery Annual Meeting (ASCRS) and at the Ophthalmology Innovation Summit at ASCRS
Apr 3, 2018
Kala Pharmaceuticals Appoints Eric Trachtenberg as General Counsel and Corporate Secretary
Mar 26, 2018
Kala Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results
Mar 19, 2018
Kala Pharmaceuticals to Report Fourth Quarter and Full Year 2017 Financial Results and Host Conference Call
Mar 14, 2018
Kala Pharmaceuticals to Present at the Oppenheimer 28th Annual Healthcare Conference
Mar 5, 2018
Kala Pharmaceuticals Appoints Gregory Perry to Board of Directors and as Audit Committee Chair
Jan 5, 2018
Kala Pharmaceuticals Announces Topline Results for Two Phase 3 Trials (STRIDE 1 and STRIDE 2) of KPI-121 0.25% in Dry Eye Disease
Jan 5, 2018
Kala Pharmaceuticals Announces New Drug Application for INVELTYS™ (KPI-121 1%) Has Been Accepted for Review by the U.S. Food and Drug Administration